25
Liberation Bioindustries has hit pause again on its 600,000-liter precision fermentation facility in Richmond, Indiana, as the contract manufacturer hunts for more capital to finish the project.
The site, which was originally slated to open by end of 2024, is now ∼75% complete. What’s left are “finishing touches” — electrical, plumbing, controls — not major equipment. The company already has fermenters and downstream processing gear on site.
A “chicken and egg” funding problem
CEO Etan Bendheim told newsmen the company has raised $70-80M in equity plus a large equipment financing package. But first-of-a-kind biomanufacturing infrastructure is too capital-heavy for typical VC, yet not revenue-generating enough for traditional project finance.
That’s created a standoff: Customers want a firm operating date before signing contracts, and lenders want firm contracts before funding construction. Bendheim called it the “everyone wants to be first to be second” problem in project finance. Liberation is now negotiating hybrid agreements — somewhere between non-binding LOIs and take-or-pay deals — to bridge the gap.
Demand isn’t the issue. Bendheim said there’s “qualified stated interest for well over 200% of the available capacity” at the plant. Prospective clients range from early-stage startups planning for 2030 to multinationals needing near-term overflow capacity. Dutch dairy protein firm Vivici is among those in talks.
Leadership shift, but confidence remains
Project lead Mark Warner is stepping back from full-time CTO to a fractional role. Warner stressed in an email to stakeholders that the move “should not be interpreted as a loss of confidence.” He said the team has kept the project on budget and in strong condition despite financing and timing challenges, and that he still believes “the long-term demand for commercial-scale biomanufacturing infrastructure will continue to grow.”
We are excited to share with you
This FREE E-Book of 50 Agritech Pioneers & Their Game Changing Innovations.
Download the Ebook now
Read Also: Biosphere: US Awards $9 Million Grant to Startup Developing Portable “Protein From Air” Bioreactors
Existing investors remain supportive while the company seeks a financing solution. There’s no hard deadline, but cash isn’t unlimited, Bendheim noted.
Why Richmond still matters
The Richmond facility is built around four 150,000-liter fermenters split into two independent trains, each with its own downstream processing. It can produce proteins, sweeteners, colors, and other ingredients using multiple organisms.
Bendheim argues a U.S.-based site remains compelling despite new capacity coming online in China, India, and Europe. “We don’t believe that the competitive set is the thing that’s holding us back,” he said.
Liberation Bioindustries’ delay adds to headwinds in U.S. biomanufacturing, where building scale-up capacity has become a bottleneck for alt-protein, ingredients, and specialty chemical startups.
